+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Vancomycin Market by Dosage Form (Lyophilized Powder For Injection, Oral Formulation, Solution For Injection), Route Of Administration (Intravenous, Oral), Indication, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Vancomycin Market by Dosage Form (Lyophilized Powder For Injection, Oral Formulation, Solution For Injection), Route Of Administration (Intravenous, Oral), Indication, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Vancomycin Market by Dosage Form (Lyophilized Powder For Injection, Oral Formulation, Solution For Injection), Route Of Administration (Intravenous, Oral), Indication, End User, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 197 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5889004
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The vancomycin market is rapidly adapting to changing clinical demands and supply chain complexities, positioning itself as an integral component of modern antimicrobial strategies. Senior leaders evaluating expansion, procurement, or technology adoption in this field need actionable market intelligence reflecting the evolving roles, regulatory shifts, and regional dynamics influencing vancomycin uptake and distribution.

Market Snapshot: Vancomycin Market Size and Projected Growth

The Vancomycin Market expanded from USD 741.53 million in 2024 to USD 779.23 million in 2025. With an expected CAGR of 4.99%, the market is projected to attain USD 993.37 million by 2030. These figures underline a strong, continuous growth trajectory anchored by rising resistance threats, evolving clinical protocols, and expanding treatment settings worldwide.

Scope & Segmentation Analysis

This report provides in-depth coverage of market segments, region-specific trends, product differentiation, and supply chain innovations shaping the vancomycin landscape.

  • Dosage Forms: Lyophilized powder for injection, oral formulations, and injection solutions.
  • Administration Routes: Intravenous and oral.
  • Indications: Clostridioides difficile infections, methicillin-resistant Staphylococcus aureus (MRSA) treatment, and surgical prophylaxis.
  • End Users: Ambulatory surgical centers (single and multi-specialty), clinics (outpatient and specialty), hospitals (community and tertiary care).
  • Distribution Channels: Hospital pharmacies, online pharmacies, and retail pharmacies.
  • Regions: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, and others), and Asia-Pacific (notably China, India, Japan, Australia, among others).
  • Leading Manufacturers: Pfizer Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Viatris Inc., Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Limited, Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Ltd.

Key Takeaways for Senior Decision-Makers

  • Vancomycin has evolved from a last-resort antibiotic to a critical first-line option across acute and outpatient care, reflecting changes in clinical stewardship and resistance trends.
  • Regulatory agencies are increasing oversight on infusion protocols and safety management, prompting formulation innovation for both oral and intravenous therapies.
  • Health systems are expanding stockpiling strategies and entering longer-term procurement contracts to address potential disruptions in the vancomycin supply chain.
  • Strategic partnerships between contract manufacturers and originators are supporting stable production, risk mitigation, and enhanced portfolio development.
  • Digital adherence tools and patient support programs are being introduced to improve outcomes and differentiate manufacturer portfolios, especially for decentralized care environments.
  • Regional approaches differ considerably—North America leads in stewardship, Western Europe prioritizes formulation stability, and Asia-Pacific focuses on manufacturing scalability and regional distribution.

Tariff Impact: Understanding U.S. Trade Policy Effects

In 2025, United States trade tariffs placed upward pressure on vancomycin manufacturing and API import costs, motivating a shift to localized production and diversified supplier arrangements. Hospital systems and distributors have responded with strategic stockpiling, renegotiated supply contracts, and phased pricing models to maintain continuity and access for patients. Ongoing consideration of regulatory incentives for onshore production and advanced analytics for risk assessment further illustrates the market’s adaptive strategies in response to trade policy volatility.

Methodology & Data Sources

This report leverages comprehensive secondary research, regulatory guideline reviews, and in-depth interviews with formulators, pharmacists, and infectious disease experts. Findings are validated through cross-referencing public regulatory data with commercial and clinical insights, ensuring robust multi-source accuracy in all market assessments.

Why This Report Matters

  • Helps senior decision-makers benchmark competitive strategies and optimize procurement amid regulatory and supply chain shifts.
  • Enables identification of emerging opportunities in dosing, administration, and regional channels supporting targeted commercial or operational initiatives.
  • Delivers actionable guidance for reinforcing supply chain resilience and responding effectively to changing trade and policy environments.

Conclusion

Vancomycin remains pivotal in addressing global antimicrobial resistance challenges and ensuring continuity of care. Informed, strategic decisions based on these insights support continued market leadership amid evolving clinical, supply, and regulatory landscapes.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emergence of vancomycin-resistant enterococci driving demand for next-generation glycopeptides
5.2. Increasing integration of therapeutic drug monitoring to optimize vancomycin dosing in critical care settings
5.3. Rising off-label use of oral vancomycin formulations for treatment of Clostridioides difficile infections in outpatient settings
5.4. Accelerated development of long-acting vancomycin analogs for reduced dosing frequency and improved patient compliance
5.5. Growing focus on cost-effective generic vancomycin supply chain strategies amid pricing pressures
5.6. Expanding research into nanoparticle-based vancomycin delivery systems enhancing targeted antimicrobial therapy
5.7. Strengthening regulatory scrutiny on vancomycin impurities prompting manufacturing process innovations
5.8. Increasing collaborations between biotech firms and academic institutions for novel vancomycin derivative discovery
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Vancomycin Market, by Dosage Form
8.1. Introduction
8.2. Lyophilized Powder For Injection
8.3. Oral Formulation
8.4. Solution For Injection
9. Vancomycin Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
10. Vancomycin Market, by Indication
10.1. Introduction
10.2. Clostridioides Difficile Infections
10.3. Methicillin Resistant Staphylococcus Aureus Treatment
10.4. Surgical Prophylaxis
11. Vancomycin Market, by End User
11.1. Introduction
11.2. Ambulatory Surgical Centers
11.2.1. Multi Specialty Centers
11.2.2. Single Specialty Centers
11.3. Clinics
11.3.1. Outpatient Clinics
11.3.2. Specialty Clinics
11.4. Hospitals
11.4.1. Community Hospitals
11.4.2. Tertiary Care Hospitals
12. Vancomycin Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Americas Vancomycin Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Vancomycin Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Vancomycin Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Pfizer Inc.
16.3.2. Teva Pharmaceutical Industries Ltd.
16.3.3. Novartis AG
16.3.4. Viatris Inc.
16.3.5. Fresenius Kabi AG
16.3.6. Hikma Pharmaceuticals PLC
16.3.7. Dr. Reddy’s Laboratories Ltd.
16.3.8. Aurobindo Pharma Limited
16.3.9. Sun Pharmaceutical Industries Ltd.
16.3.10. Glenmark Pharmaceuticals Ltd.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. VANCOMYCIN MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL VANCOMYCIN MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL VANCOMYCIN MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL VANCOMYCIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 6. GLOBAL VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL VANCOMYCIN MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL VANCOMYCIN MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL VANCOMYCIN MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL VANCOMYCIN MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS VANCOMYCIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS VANCOMYCIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES VANCOMYCIN MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES VANCOMYCIN MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. VANCOMYCIN MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. VANCOMYCIN MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. VANCOMYCIN MARKET: RESEARCHAI
FIGURE 26. VANCOMYCIN MARKET: RESEARCHSTATISTICS
FIGURE 27. VANCOMYCIN MARKET: RESEARCHCONTACTS
FIGURE 28. VANCOMYCIN MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. VANCOMYCIN MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL VANCOMYCIN MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL VANCOMYCIN MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL VANCOMYCIN MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL VANCOMYCIN MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL VANCOMYCIN MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL VANCOMYCIN MARKET SIZE, BY LYOPHILIZED POWDER FOR INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL VANCOMYCIN MARKET SIZE, BY LYOPHILIZED POWDER FOR INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL VANCOMYCIN MARKET SIZE, BY ORAL FORMULATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL VANCOMYCIN MARKET SIZE, BY ORAL FORMULATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL VANCOMYCIN MARKET SIZE, BY SOLUTION FOR INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL VANCOMYCIN MARKET SIZE, BY SOLUTION FOR INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL VANCOMYCIN MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL VANCOMYCIN MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL VANCOMYCIN MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL VANCOMYCIN MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL VANCOMYCIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL VANCOMYCIN MARKET SIZE, BY CLOSTRIDIOIDES DIFFICILE INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL VANCOMYCIN MARKET SIZE, BY CLOSTRIDIOIDES DIFFICILE INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL VANCOMYCIN MARKET SIZE, BY METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS TREATMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL VANCOMYCIN MARKET SIZE, BY METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS TREATMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL VANCOMYCIN MARKET SIZE, BY SURGICAL PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL VANCOMYCIN MARKET SIZE, BY SURGICAL PROPHYLAXIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL VANCOMYCIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL VANCOMYCIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL VANCOMYCIN MARKET SIZE, BY MULTI SPECIALTY CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL VANCOMYCIN MARKET SIZE, BY MULTI SPECIALTY CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL VANCOMYCIN MARKET SIZE, BY SINGLE SPECIALTY CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL VANCOMYCIN MARKET SIZE, BY SINGLE SPECIALTY CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL VANCOMYCIN MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL VANCOMYCIN MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL VANCOMYCIN MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL VANCOMYCIN MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL VANCOMYCIN MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL VANCOMYCIN MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL VANCOMYCIN MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL VANCOMYCIN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL VANCOMYCIN MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL VANCOMYCIN MARKET SIZE, BY COMMUNITY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL VANCOMYCIN MARKET SIZE, BY COMMUNITY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL VANCOMYCIN MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL VANCOMYCIN MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL VANCOMYCIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL VANCOMYCIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL VANCOMYCIN MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL VANCOMYCIN MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL VANCOMYCIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL VANCOMYCIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS VANCOMYCIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS VANCOMYCIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS VANCOMYCIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS VANCOMYCIN MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS VANCOMYCIN MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES VANCOMYCIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES VANCOMYCIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES VANCOMYCIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES VANCOMYCIN MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES VANCOMYCIN MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES VANCOMYCIN MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 101. CANADA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 102. CANADA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 103. CANADA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 104. CANADA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 105. CANADA VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 106. CANADA VANCOMYCIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 107. CANADA VANCOMYCIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 108. CANADA VANCOMYCIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 109. CANADA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
TABLE 110. CANADA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2030 (USD MILLION)
TABLE 111. CANADA VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 112. CANADA VANCOMYCIN MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 113. CANADA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 114. CANADA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 115. CANADA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 116. CANADA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 117. MEXICO VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 118. MEXICO VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 119. MEXICO VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 120. MEXICO VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 121. MEXICO VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 122. MEXICO VANCOMYCIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 123. MEXICO VANCOMYCIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 124. MEXICO VANCOMYCIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 125. MEXICO VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
TABLE 126. MEXICO VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2030 (USD MILLION)
TABLE 127. MEXICO VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 128. MEXICO VANCOMYCIN MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 129. MEXICO VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 130. MEXICO VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 131. MEXICO VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 132. MEXICO VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 133. BRAZIL VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 134. BRAZIL VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL VANCOMYCIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL VANCOMYCIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL VANCOMYCIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL VANCOMYCIN MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 149. ARGENTINA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 150. ARGENTINA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA VANCOMYCIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA VANCOMYCIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA VANCOMYCIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA VANCOMYCIN MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 163. ARGENTINA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 164. ARGENTINA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA VANCOMYCIN MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 184. UNITED KINGDOM VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 186. UNITED KINGDOM VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 188. UNITED KINGDOM VANCOMYCIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM VANCOMYCIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM VANCOMYCIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM VANCOMYCIN MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 196. UNITED KINGDOM VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 198. UNITED KINGDOM VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 199. GERMANY VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 200. GERMANY VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 201. GERMANY VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 202. GERMANY VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 203. GERMANY VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 204. GERMANY VANCOMYCIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 205. GERMANY VANCOMYCIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 206. GERMANY VANCOMYCIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 207. GERMANY VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
TABLE 208. GERMANY VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2030 (USD MILLION)
TABLE 209. GERMANY VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 210. GERMANY VANCOMYCIN MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 211. GERMANY VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 212. GERMANY VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 213. GERMANY VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 214. GERMANY VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 215. FRANCE VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 216. FRANCE VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 217. FRANCE VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 218. FRANCE VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 219. FRANCE VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 220. FRANCE VANCOMYCIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 221. FRANCE VANCOMYCIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 222. FRANCE VANCOMYCIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 223. FRANCE VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
TABLE 224. FRANCE VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2030 (USD MILLION)
TABLE 225. FRANCE VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 226. FRANCE VANCOMYCIN MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 227. FRANCE VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 228. FRANCE VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 229. FRANCE VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 230. FRANCE VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 231. RUSSIA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 232. RUSSIA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 233. RUSSIA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 234. RUSSIA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 235. RUSSIA VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 236. RUSSIA VANCOMYCIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 237. RUSSIA VANCOMYCIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 238. RUSSIA VANCOMYCIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 239. RUSSIA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
TABLE 240. RUSSIA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2030 (USD MILLION)
TABLE 241. RUSSIA VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 242. RUSSIA VANCOMYCIN MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 243. RUSSIA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 244. RUSSIA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 245. RUSSIA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 246. RUSSIA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 247. ITALY VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 248. ITALY VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 249. ITALY VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 250. ITALY VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 251. ITALY VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 252. ITALY VANCOMYCIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 253. ITALY VANCOMYCIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 254. ITALY VANCOMYCIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 255. ITALY VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
TABLE 256. ITALY VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2030 (USD MILLION)
TABLE 257. ITALY VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 258. ITALY VANCOMYCIN MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 259. ITALY VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 260. ITALY VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 261. ITALY VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 262. ITALY VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 263. SPAIN VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 264. SPAIN VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 265. SPAIN VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 266. SPAIN VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 267. SPAIN VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 268. SPAIN VANCOMYCIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 269. SPAIN VANCOMYCIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 270. SPAIN VANCOMYCIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 271. SPAIN VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
TABLE 272. SPAIN VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2030 (USD MILLION)
TABLE 273. SPAIN VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 274. SPAIN VANCOMYCIN MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 275. SPAIN VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 276. SPAIN VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 277. SPAIN VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 278. SPAIN VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 279. UNITED ARAB EMIRATES VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 280. UNITED ARAB EMIRATES VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES VANCOMYCIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES VANCOMYCIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES VANCOMYCIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2030 (USD MILLION)
TABLE 289. UNITED ARAB EMIRATES VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 290. UNITED ARAB EMIRATES VANCOMYCIN MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 291. UNITED ARAB EMIRATES VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 292. UNITED ARAB EMIRATES VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 293. UNITED ARAB EMIRATES VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 294. UNITED ARAB EMIRATES VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 295. SAUDI ARABIA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 296. SAUDI ARABIA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 297. SAUDI ARABIA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 298. SAUDI ARABIA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 299. SAUDI ARABIA VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 300. SAUDI ARABIA VANCOMYCIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 301. SAUDI ARABIA VANCOMYCIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 302. SAUDI ARABIA VANCOMYCIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 303. SAUDI ARABIA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
TABLE 304. SAUDI ARABIA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2030 (USD MILLION)
TABLE 305. SAUDI ARABIA VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 306. SAUDI ARABIA VANCOMYCIN MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 308. SAUDI ARABIA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 309. SAUDI ARABIA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 310. SAUDI ARABIA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 311. SOUTH AFRICA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 312. SOUTH AFRICA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 313. SOUTH AFRICA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 314. SOUTH AFRICA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 315. SOUTH AFRICA VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 316. SOUTH AFRICA VANCOMYCIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 317. SOUTH AFRICA VANCOMYCIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 318. SOUTH AFRICA VANCOMYCIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 319. SOUTH AFRICA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
TABLE 320. SOUTH AFRICA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2030 (USD MILLION)
TABLE 321. SOUTH AFRICA VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 322. SOUTH AFRICA VANCOMYCIN MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 323. SOUTH AFRICA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 324. SOUTH AFRICA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 325. SOUTH AFRICA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 326. SOUTH AFRICA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 327. DENMARK VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 328. DENMARK VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 329. DENMARK VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 330. DENMARK VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 331. DENMARK VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 332. DENMARK VANCOMYCIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 333. DENMARK VANCOMYCIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 334. DENMARK VANCOMYCIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 335. DENMARK VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
TABLE 336. DENMARK VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2030 (USD MILLION)
TABLE 337. DENMARK VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 338. DENMARK VANCOMYCIN MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 339. DENMARK VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 340. DENMARK VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 341. DENMARK VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 342. DENMARK VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 343. NETHERLANDS VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 344. NETHERLANDS VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 345. NETHERLANDS VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 346. NETHERLANDS VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 347. NETHERLANDS VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 348. NETHERLANDS VANCOMYCIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 349. NETHERLANDS VANCOMYCIN MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 350. NETHERLANDS VANCOMYCIN MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 351. NETHERLANDS VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
TABLE 352. NETHERLANDS VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2030 (USD MILLION)
TABLE 353. NETHERLANDS VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 354. NETHERLANDS VANCOMYCIN MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 355. NETHERLANDS VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 356. NETHERLANDS VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 357. NETHERLANDS VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 358. NETHERLANDS VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 359. QATAR VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 360. QATAR VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 361. QATAR VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 362. QATAR VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 363. QATAR VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 364. QATAR VANCOMYCIN MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 365. QATAR VANCOMYCIN MARKET SIZE, BY END USER, 2018-2024 (USD MI

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Vancomycin market report include:
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Viatris Inc.
  • Fresenius Kabi AG
  • Hikma Pharmaceuticals PLC
  • Dr. Reddy’s Laboratories Ltd.
  • Aurobindo Pharma Limited
  • Sun Pharmaceutical Industries Ltd.
  • Glenmark Pharmaceuticals Ltd.

Table Information

Report AttributeDetails
No. of Pages197
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 779.23 Million
Forecasted Market Value ( USD ) by 2030 $ 993.37 Million
Compound Annual Growth Rate4.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Vancomycin Hydrochloride Capsules Market by Packaging (Blister Pack, Bottle), Patient Type (Adult, Pediatric), Product Type, End Use, Distribution Channel, Strength - Global Forecast 2025-2030 - Product Image

Vancomycin Hydrochloride Capsules Market by Packaging (Blister Pack, Bottle), Patient Type (Adult, Pediatric), Product Type, End Use, Distribution Channel, Strength - Global Forecast 2025-2030

  • Report
  • 194 Pages
  • Global
From
Vancomycin - Global Strategic Business Report - Product Image

Vancomycin - Global Strategic Business Report

  • Report
  • 78 Pages
  • Global
From
Vancomycin Market Report 2025 - Product Image

Vancomycin Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Vancomycin Global Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Application - Product Image

Vancomycin Global Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Application

  • Report
  • 96 Pages
  • Global
From
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Insight, 2025 - Product Image

Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From

About the Vancomycin Market

Vancomycin is an antibiotic used to treat a wide range of bacterial infections. It is a glycopeptide antibiotic, derived from the bacterium Amycolatopsis orientalis, and is used to treat infections caused by Gram-positive bacteria. Vancomycin is often used as a last-resort antibiotic, when other antibiotics have failed to treat an infection. It is also used to treat infections caused by Clostridium difficile, a bacterium that can cause severe diarrhea. Vancomycin is available in both oral and intravenous forms, and is used to treat a variety of infections, including skin and soft tissue infections, bone and joint infections, and endocarditis. It is also used to treat infections caused by methicillin-resistant Staphylococcus aureus (MRSA). Vancomycin is a widely used antibiotic, and is available from a number of pharmaceutical companies, including Pfizer, Merck, and AstraZeneca. It is also available in generic form from a number of generic drug manufacturers. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.